HBV reactivation after fludarabine chemotherapy identified on investigation of suspected transfusion-transmitted Hepatitis B virus

Journal of Hepatology

Volumn 53, Issue 4, 2010, Pages 780-787

  Power, J P ^a   El Chaar, M ^b   Temple, J ^b   Thomas, M ^a   Spillane, D ^a   Candotti, D ^c   Allain, J P ^b  

^a St Finbarr's Hospital   (Ireland)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

Chlorambucil; Fludarabine; HBsAg mutant; HBV; Reactivation; Transfusion transmitted Hepatitis B virus (TT HBV)

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKYLATING AGENT; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; CYTOTOXIC AGENT; FLUDARABINE; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT PROTEIN; VIRUS DNA;

ACUTE HEPATITIS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SUBSTITUTION; ANTIBODY DETECTION; ANTIGEN DETECTION; ANTIGENICITY; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; FAMILY HISTORY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HOSPITAL ADMISSION; HUMAN; HYPERBILIRUBINEMIA; IMMUNOASSAY; MALE; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; PANCYTOPENIA; PHYLOGENETIC TREE; POSTTRANSFUSION HEPATITIS; PRIORITY JOURNAL; SEPSIS; SEROLOGY; SITE DIRECTED MUTAGENESIS; UNINDEXED SEQUENCE; VIRUS DETECTION; VIRUS MUTANT; VIRUS REACTIVATION;

ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; DISEASE TRANSMISSION, INFECTIOUS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; VIDARABINE; VIRUS ACTIVATION;

EID: 77956263516     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.04.034     Document Type: Article

References (33)

1. W. Yeo, P.K. Chan, S. Zhong, W.M. Ho, J.L. Steinberg, and J.S. Tam Frequency of hepatitis B viral reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors J Med Virol 62 2000 299 307
2. G. Lalazar, D. Rund, and D. Shouval Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies Br J Haematol 136 2007 699 712
3. J.J. Lefrre, A. Servant-Delmas, D. Candotti, M. Mariotti, I. Thomas, and Y. Brossard Persistent B19 infection in immunocompetent individuals: implications for transfusion safety Blood 106 2005 2890 2895
4. B. Rehermann, C. Ferrari, C. Pasquinelli, and F.V. Chisari The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response Nat Med 2 1996 1104 1108
5. B. Roche, D. Samuel, M. Gigou, C. Feray, V. Virot, and L. Schmets De novo and apparent de novo hepatitis B virus infection after liver transplantation J Hepatol 26 1997 517 526
6. G. Lalazar, D. Rund, and D. Shouval Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies Br J Haematol 136 2007 699 712
7. A. Zahn, C. Li, K. Danso, D. Candotti, S. Owusu-Ofori, and J. Temple Molecular characterization of occult hepatitis B virus in genotype E-infected subjects J Gen Virol 89 2008 409 418
8. J.P. Allain, P.E. Hewitt, R.S. Tedder, and L.M. Williamson Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion Br J Haematol 107 1999 186 195
9. S.H. Kleinman, and M.P. Bush HBV: amplified and back in the safety spotlight Transfusion 41 2001 1081 1085
10. J. Pillonel, and S. Laperche Le groupe Agents Transmissibles par Transfusion de la Societe francaise de transfusion sanguine. Trends in residual risk of transfusion transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of nucleic acid testing Transfus Clin Biol 11 2004 81 86
11. C.R. Seed, P. Kiely, and J. Keller Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus Intern Med J 35 2005 592 598
12. T. O'Connel, L. Thornton, D. O'flanagan, A. Staines, J. O'connell, and S. Dooley Prevalence of hepatitis B anti-core antibody in the republic of Ireland Epidemiol Infect 125 2000 701 704
13. National Haemovigilance Office. Annual Report 2004, Dublin, Ireland; 2004.
14. G. Raimondo, J.P. Allain, M.R. Brunetto, M.A. Buendia, D.S. Chen, and M. Colombo Statements from the Taormina expert meeting on occult hepatitis B virus infection J Hepatol 49 2008 652 657
15. Serious Hazards of Transfusion (SHOT). Annual Report 2004, Manchester, UK; 2004.
16. D. Lundy, S. Laspina, H. Kaplan, B. Rabin Fastman, and E. Lawlor Seven hundred and fifty-nine (759) chances to learn: a 3-year pilot project to analyse transfusion-related near-miss events in the Republic of Ireland Vox Sang 92 2007 233 241
17. M. Horgan, E. Brannigan, B. Crowley, J. Levis, and L.J. Fanning Hepatitis B genotype and YMDD profiles in an untreated Irish population J Clin Virol 35 2006 203 204
18. C. Blanpain, C. Knoop, M.L. Delforge, M. Antoine, M.O. Peny, and C. Liesnard Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: report on three cases and review of the literature Transplantation 66 1998 883 886
19. N. Dhedin, C. Douvin, M. Kuentz, M.F. Saint-Marc, O. Reman, and C. Rieux Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc Transplantation 66 1998 616 619
20. B. Roche, C. Feray, M. Gigou, A.M. Roque-Afonso, J.L. Arulnaden, and V. Delvart HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis Hepatology 38 2003 86 95
21. C. Berasain, M. Betes, A. Panizo, J. Ruiz, J.I. Herrero, and M.P. Civeira Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology Gut 47 2000 429 435
22. A. Alexopoulou, M. Theodorou, S.P. Dourakis, P. Karayiannis, E. Sagkana, and K. Papanikolopoulos Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations J Viral Hep 13 2006 591 596
23. X. Huang, D. Lu, G. Ji, Y. Sun, L. Ma, and Z. Chen Hepatitis B virus (HBV) vaccine-induced escape mutants of HBV S gene among children from Qidong area, China Virus Res 99 2004 63 68
24. H.Y. Hsu, M.H. Chang, Y.H. Ni, and H.L. Chen Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan Gut 53 2004 1499 1503
25. X. Zheng, K.M. Weinberger, R. Gehrke, M. Isogawa, G. Hilken, and T. Kemper Mutant hepatitis B virus surface antigens (HBsAg) are immunogenic but may have changed specificity Virology 329 2004 454 464
26. S. Awerkiew, M. Daumer, M. Reiser, U.C. Wend, H. Pfister, and R. Kaiser Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient J Clin Virol 38 2007 83
27. S. Grethe, M. Monazahian, I. Böhme, and R. Thomssen Characterization of unusual escape variants of hepatitis B virus isolated from a hepatitis B surface antigen-negative subject J Virol 72 1998 7692 7696
28. L.A. Wallace, J.E. Echevarria, J.M. Echevarria, and W.F. Carman Molecular characterization of envelope antigenic variants of hepatitis B virus from Spain J Infect Dis 170 1994 1300 1303
29. D. Candotti, P. Grabarczyk, P. Ghiazza, R. Roig, N. Casamitjana, and P. Iudicone Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains J Hepatol 49 2008 537 547
30. H.Y. Lu, Z. Zeng, X.Y. Xu, N.L. Zhang, M. Yu, and W.B. Gong Mutations in surface and polymerase gene of chronic hepatitis B patients with coexisting HBsAg and anti-HBs World J Gastroenterol 12 2006 4219 4223
31. V.A. Morrison, K.R. Rai, B.L. Peterson, J.E. Kolitz, L. Elias, and F.R. Appelbaum Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: intergroup study cancer and leukemia group B 9011 J Clin Oncol 19 2001 3611 3621
32. M. Picardi, F. Pane, C. Quintarelli, A. De Renzo, A. Del Giudice, and B. De Divitiis Hep B virus reactivation after fludarabine based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations Haematologica 88 2003 1296 1303
33. R. Miller, P.E. Hewitt, R. Warwick, M.C. Moore, and B. Vincent Review of counselling in a transfusion service: the London (UK) experience Vox Sang 74 1998 133 139